Overview Dividends

(DVAX) Dynavax Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2681582019

Hepatitis B Vaccine, Adjuvant, Plague Vaccine, Shingles Vaccine

Biotechnology
Market Cap in USD: 1,275m

IPO / Inception: 2004-02-19
Return 12m vs S&P 500: 1.63%

EPS (Earnings per Share)

EPS CAGR: -22.64%
EPS Trend: -53.5%

Last SUE: 1.71
Qual. Beats: 1

Revenue

Rev. CAGR: -17.49%
Rev. Trend: -51.1%

Last SUE: 0.16
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	32.9%
Value at Risk 5%th	49.8%
Relative Tail Risk	-8.06%

Reward TTM
Sharpe Ratio	0.50
Alpha	8.54
CAGR/Max DD	0.35

Character TTM
Hurst Exponent	0.334
Beta	0.539
Beta Downside	0.663

Drawdowns 3y
Max DD	37.56%
Mean DD	17.26%
Median DD	16.75%

Description: DVAX Dynavax Technologies November 15, 2025

Dynavax Technologies (NASDAQ: DVAX) is a commercial-stage biopharma that develops and markets vaccines primarily in the United States, with a growing international footprint. Its flagship product, HEPLISAV-B, is a three-dose hepatitis B vaccine approved for adults ≥ 18 years and delivered through hospitals, clinics, public-health entities, the Department of Defense, the VA, and retail pharmacy channels.

The pipeline leverages Dynavax’s CpG 1018 adjuvant platform and includes rF1V, a plague vaccine currently in Phase 2, and Z-1018, a shingles vaccine in Phase 1/2 targeting adults ≥ 50 years. The company is also pursuing an indication of HEPLISAV-B for patients on hemodialysis, a high-risk group with unmet vaccination needs.

Dynavax distributes its products via wholesalers and specialty distributors and maintains strategic collaborations with the U.S. Department of Defense, CEPI, Zhejiang Clover Biopharmaceuticals, Clover Biopharma (Hong Kong), and Biological E Limited, which expand its manufacturing capacity and market access in Asia.

Key performance indicators: FY 2023 revenue was approximately $120 million, with HEPLISAV-B contributing > 90 % of sales; the company reported a 12 % year-over-year increase in vaccine shipments driven by expanded formulary placement in integrated delivery networks. Sector drivers include a projected 6 % CAGR for the U.S. vaccine market through 2029 and rising demand for adjuvant-enhanced vaccines as aging demographics boost shingles and hepatitis B immunization volumes.

For a deeper quantitative assessment of Dynavax’s valuation dynamics, you may find the analytics on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-43.4m TTM) > 0 and > 6% of Revenue (6% = 19.8m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 6.37pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 214.1% (prev 328.3%; Δ -114.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.10 (>3.0%) and CFO 90.6m > Net Income -43.4m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 7.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (136.5m) change vs 12m ago -11.85% (target <= -2.0% for YES)

Gross Margin 83.17% (prev 82.85%; Δ 0.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 32.91% (prev 24.56%; Δ 8.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -5.28 (EBITDA TTM -25.6m / Interest Expense TTM 6.41m) >= 6 (WARN >= 3)

Altman Z'' -1.03

(A) 0.75 = (Total Current Assets 814.3m - Total Current Liabilities 106.8m) / Total Assets 946.5m

(B) -1.01 = Retained Earnings (Balance) -953.7m / Total Assets 946.5m

warn (B) unusual magnitude: -1.01 — check mapping/units

(D) -2.31 = Book Value of Equity -952.8m / Total Liabilities 412.4m

Total Rating: -1.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 38.52

1. Piotroski 3.50pt

2. FCF Yield 8.83%

3. FCF Margin 24.37%

4. Debt/Equity 0.53

5. Debt/Ebitda -4.86

6. ROIC - WACC (= -10.68)%

7. RoE -8.05%

8. Rev. Trend -51.07%

9. EPS Trend -53.48%

What is the price of DVAX shares?

As of December 27, 2025, the stock is trading at USD 15.38 with a total of 6,095,632 shares traded.
Over the past week, the price has changed by +41.62%, over one month by +34.56%, over three months by +57.26% and over the past year by +18.04%.

Is DVAX a buy, sell or hold?

Dynavax Technologies has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy DVAX.

Strong Buy: 2
Buy: 1
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the DVAX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	19.3	25.2%
Analysts Target Price	19.3	25.2%
ValueRay Target Price	15.2	-1.3%

DVAX Fundamental Data Overview December 21, 2025

Market Cap USD = 1.28b (1.28b USD * 1.0 USD.USD)
P/E Forward = 57.4713
P/S = 3.8583
P/B = 2.3897
Beta = 0.885
Revenue TTM = 330.5m USD
EBIT TTM = -33.9m USD
EBITDA TTM = -25.6m USD
Long Term Debt = 221.0m USD (from longTermDebt, last quarter)
Short Term Debt = 40.1m USD (from shortTermDebt, last quarter)
Debt = 285.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 124.8m USD (from netDebt column, last quarter)
Enterprise Value = 912.4m USD (1.28b + Debt 285.0m - CCE 647.8m)
Interest Coverage Ratio = -5.28 (Ebit TTM -33.9m / Interest Expense TTM 6.41m)
FCF Yield = 8.83% (FCF TTM 80.5m / Enterprise Value 912.4m)
FCF Margin = 24.37% (FCF TTM 80.5m / Revenue TTM 330.5m)
Net Margin = -13.13% (Net Income TTM -43.4m / Revenue TTM 330.5m)
Gross Margin = 83.17% ((Revenue TTM 330.5m - Cost of Revenue TTM 55.6m) / Revenue TTM)
Gross Margin QoQ = 84.82% (prev 85.29%)
Tobins Q-Ratio = 0.96 (Enterprise Value 912.4m / Total Assets 946.5m)
Interest Expense / Debt = 0.48% (Interest Expense 1.38m / Debt 285.0m)
Taxrate = 5.25% (1.49m / 28.4m)
NOPAT = -32.1m (EBIT -33.9m * (1 - 5.25%)) [loss with tax shield]
Current Ratio = 7.62 (Total Current Assets 814.3m / Total Current Liabilities 106.8m)
Debt / Equity = 0.53 (Debt 285.0m / totalStockholderEquity, last quarter 534.1m)
Debt / EBITDA = -4.86 (negative EBITDA) (Net Debt 124.8m / EBITDA -25.6m)
Debt / FCF = 1.55 (Net Debt 124.8m / FCF TTM 80.5m)
Total Stockholder Equity = 539.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.59% (Net Income -43.4m / Total Assets 946.5m)
RoE = -8.05% (Net Income TTM -43.4m / Total Stockholder Equity 539.0m)
RoCE = -4.46% (EBIT -33.9m / Capital Employed (Equity 539.0m + L.T.Debt 221.0m))
RoIC = -4.06% (negative operating profit) (NOPAT -32.1m / Invested Capital 790.6m)
WACC = 6.62% (E(1.28b)/V(1.56b) * Re(8.0%) + D(285.0m)/V(1.56b) * Rd(0.48%) * (1-Tc(0.05)))
Discount Rate = 8.0% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 1.19%
[DCF Debug] Terminal Value 73.99% ; FCFE base≈57.4m ; Y1≈44.5m ; Y5≈28.5m
Fair Price DCF = 4.54 (DCF Value 532.8m / Shares Outstanding 117.4m; 5y FCF grow -26.66% → 3.0% )
EPS Correlation: -53.48 | EPS CAGR: -22.64% | SUE: 1.71 | # QB: 1
Revenue Correlation: -51.07 | Revenue CAGR: -17.49% | SUE: 0.16 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.02 | Chg30d=+0.040 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.33 | Chg30d=-0.020 | Revisions Net=+1 | Growth EPS=+166.0% | Growth Revenue=+15.8%

Additional Sources for DVAX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle